Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Irving Carr

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Biomedical Research & Environmental Sciences|October 22, 2025
Inflammation Markers and HCC AggressivenessBrian Irving Carr, Rossella Donghia
Oncology|April 8, 2025
Factors Relating to Tumor Size and Survival in Patients with Hepatocellular Carcinoma: Significance of Platelet-Lymphocyte Ratio, Portal Vein Thrombosis, and AlbuminRossella Donghia, Brian Irving Carr, Sezai Yilmaz
Journal of Clinical Gastroenterology|September 17, 2011
Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinomaBrian Irving Carr, Klaus Bron, Dennis P Swanson
Journal of Inonu Liver Transplantation Institute|September 3, 2025
A Network Phenotyping Strategy approach in a Turkish HCC Dataset and Comparison of Patients Selected for Transplant and those who were notPetr Pancoska, Brian Irving Carr, Volkan Ince, et al.
Cancers|March 14, 2020
Inflammatory Mechanisms of HCC DevelopmentMaria Grazia Refolo, Caterina Messa, Vito Guerra, et al.
Hepatology Forum|March 15, 2024
HBV viral load and tumor and non-tumor factors in patients with HBV-associated HCCEngin Ataman, Murat Harputluoglu, Brian Irving Carr, et al.
Cancer Chemotherapy and Pharmacology|April 25, 2015
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factorRosalba D'Alessandro, Maria Grazia Refolo, Catia Lippolis, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 3, 2015
Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1Catia Lippolis, Maria Grazia Refolo, Rosalba D'Alessandro, et al.
Cancers|June 12, 2019
Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and MotilityRosalba D'Alessandro, Maria Grazia Refolo, Palma Aurelia Iacovazzi, et al.
Oncotarget|December 22, 2017
IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell linesMaria Grazia Refolo, Rosalba D'Alessandro, Catia Lippolis, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Biomedical Research & Environmental Sciences|October 22, 2025
Inflammation Markers and HCC AggressivenessBrian Irving Carr, Rossella Donghia
Oncology|April 8, 2025
Factors Relating to Tumor Size and Survival in Patients with Hepatocellular Carcinoma: Significance of Platelet-Lymphocyte Ratio, Portal Vein Thrombosis, and AlbuminRossella Donghia, Brian Irving Carr, Sezai Yilmaz
Journal of Clinical Gastroenterology|September 17, 2011
Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinomaBrian Irving Carr, Klaus Bron, Dennis P Swanson
Journal of Inonu Liver Transplantation Institute|September 3, 2025
A Network Phenotyping Strategy approach in a Turkish HCC Dataset and Comparison of Patients Selected for Transplant and those who were notPetr Pancoska, Brian Irving Carr, Volkan Ince, et al.
Cancers|March 14, 2020
Inflammatory Mechanisms of HCC DevelopmentMaria Grazia Refolo, Caterina Messa, Vito Guerra, et al.
Hepatology Forum|March 15, 2024
HBV viral load and tumor and non-tumor factors in patients with HBV-associated HCCEngin Ataman, Murat Harputluoglu, Brian Irving Carr, et al.
Cancer Chemotherapy and Pharmacology|April 25, 2015
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factorRosalba D'Alessandro, Maria Grazia Refolo, Catia Lippolis, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 3, 2015
Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1Catia Lippolis, Maria Grazia Refolo, Rosalba D'Alessandro, et al.
Cancers|June 12, 2019
Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and MotilityRosalba D'Alessandro, Maria Grazia Refolo, Palma Aurelia Iacovazzi, et al.
Oncotarget|December 22, 2017
IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell linesMaria Grazia Refolo, Rosalba D'Alessandro, Catia Lippolis, et al.
Pageof 2